TM4SF1与脑胶质瘤病理分级及预后的相关性

目的 探讨跨膜四蛋白超家族成员1（TM4SF1）与脑胶质瘤病理分级及预后的相关性。方法 应用生信分析方法，计算机检索TCGA数据库，采用GEPIA分析TM4SF1表达胶质瘤病理分级及生存预后的关系。收集2014年3月至2017年4月手术切除的脑胶质瘤83例低级别胶质瘤（LGG）35例和高级别胶质瘤（HGG）48例]和23例颅脑损伤内减压术切除的非肿瘤脑组织为对照，采用免疫组化染色法检测组织TM4SF1表达情况，术后随访4年，记录无进展生存期（PFS）和总生存期（OS）。结果 生信分析显示:胶质瘤组织TM4SF1 mRNA表达量明显高于正常脑组织（P<0.05）；而且，HGG组织TM4SF1 mRNA表达量明显高于LGG组织（P<0.05）。TM4SF1高表达HGG病人OS较低表达病人明显缩短（P<0.05）；TM4SF1高表达LGG病人PFS、OS较低表达病人均明显缩短（P<0.05）。临床病例分析显示:胶质瘤TM4SF1高表达率50.60%（42/83）]明显高于非肿瘤脑组织13.04%（3/23）；P<0.01]；HGG组织TM4SF1高表达率60.42%（29/48）]明显高于LGG组织37.14%（13/35）；P<0.05]；多因素Cox比例回归风险模型分析显示，TM4SF1高表达是胶质瘤病人生存预后不良的独立危险因素（P<0.05）；生存曲线分析显示，TM4SF1 高表达病人中位PFS和OS较低表达病人明显缩短（P<0.05）。结论 脑胶质瘤TM4SF1呈高表达，与肿瘤病理分级、不良生存预后有关。

Relationship between expression of TM4SF1 in glioma tissues and malignancy and prognosis of gliomas

Objective To investigate the relationship between the expression of transmembrane-4-L-six-family-1 (TM4SF1) in glioma tissues and the malignancy and prognosis of gliomas. Methods The TCGA database was searched by computer to analyze the relationship between TM4SF1 expression and pathological grade and survival prognosis of glioma patients using bioinformatics analysis method GEPIA. The expressions of TM4SF1 were detected using immunohistochemical staining in glioma tissues obtained from 83 glioma patients 35 low-grade glioma (LGG) and 48 high-grade glioma (HGG)] who underwent surgery from March 2014 to April 2017 and in non-tumor tissues obtained from 23 patients with traumatic brain injury who underwent decompression. These 83 glioma pstients were followed up for 4 years, and the progression-free survival (PFS) and overall survival (OS) were recorded. Results Bioinformatics analysis showed that the expression of TM4SF1 mRNA in glioma tissues was significantly higher than that in normal brain tissue (P<0.05); the expression of TM4SF1 mRNA in HGG tissues was significantly higher than that in LGG tissues (P<0.05); the OS of HGG patients with high expression of TM4SF1 was significantly shorter than that of HGG patients with low expression of TM4SF1 (P<0.05); the PFS and OS of LGG patients with high expression of TM4SF1 were significantly shorter than that of LGG patients with low expression of TM4SF1 (P<0.05). Analysis of clinical cases showed that the high expression rate of TM4SF1 in glioma tissues 50.60% (42/83)] was significantly higher than that in non-tumor brain tissues 13.04% (3/23); P<0.01]; the high expression rate of TM4SF1 in HGG tissues 60.42% (29/48)] was significantly higher than that of LGG tissue 37.14% (13/35); P<0.05]; multivariate Cox proportional regression hazard model analysis showed that high expression of TM4SF1 was an independent risk factor of poor survival prognosis in glioma patients (P<0.05); survival curve analysis showed that the median PFS and OS of patients with high TM4SF1 expression were significantly shorter than those of patients with low TM4SF1 expression (P<0.05). Conclusions The expression of TM4SF1 in gliomas is up-regulated, which is related to the pathological grade and poor survival prognosis.